Cite

HARVARD Citation

    Nuvolone, M. et al. (2021). A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis. Expert opinion on drug safety. 20 (4), pp. 411-426. [Online]. 
  
Back to record